IRVINE, CALIFORNIA, June 30, 2015 – Inari Medical, Inc. announced today that it has closed a $12.4 million Series B venture capital financing. The financing was led by members of the board of directors and returning investors Versant Ventures and US Venture Partners. The round also included participation by several medical device industry veterans.
“We are very pleased to complete this financing with the support of new and existing investors,” said Bill Hoffman, who joined in February 2015 as President and Chief Executive Officer. “These funds will allow us to significantly enhance company value with continued product improvements and clinical studies that demonstrate the value of the FlowTriever™ Retrieval/Aspiration System in several markets with important unmet needs.” The FlowTriever is an FDA cleared, catheter-based thrombectomy device shown to extract significant amounts of clot from large vessels. “Inari’s approach to emboli retrieval is novel. It provides the interventionalist with a tool that can substantially reduce the need for thrombolytics, which carry unacceptably high risk for many patients,” added Bob Rosenbluth, Chairman and Co-founder.
About Inari Medical
Inari Medical, founded in 2013, is a venture capital backed medical device company formed by Inceptus Medical. Inari is developed a system for the interventional treatment of vascular thrombus and emboli. The company is backed by Versant Ventures, U.S. Venture Partners, the founders, and other private investors.
For more information, visit the company’s website at inarimedical.com.
Bill Hoffman, Chief Executive Officer, Inari Medical Inc.